Cost-effectiveness analysis of cefoperazone sulbactam sodium in nosocomial infection / 中国生化药物杂志
Chinese Journal of Biochemical Pharmaceutics
; (6): 342-343, 2017.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-620553
Biblioteca responsável:
WPRO
ABSTRACT
Objective To investigate the cost-effectiveness of cefoperazone sulbactam sodium in treating nosocomial infection (lower respiratory tract infection).Methods 80 cases of nosocomial infection in Jincheng Second People's Hospital from January 2014 to January 2017 were treated as the subjects:
the observation group was treated with cefoperazone sulbactam sodium and the control group was treated with cefodizime sodium.The data of two groups of patients were recorded and the data were analyzed statistically.The cost-effectiveness of cefoperazone sulbactam sodium in hospital infection was discussed.Results There was no significant difference in the clinical curative effect between the two groups.The cost of observation group (cefoperazone sulbactam sodium) was lower than that of the control group (cefodizime sodium), the difference was statistically significant (P< 0.05).Conclusion Patients with nosocomial infection choose to use cefoperazone sulbactam sodium as the treatment method, which has exact clinical efficacy, high cost-effectiveness.It is worthy of clinical wide application.
Texto completo:
Disponível
Contexto em Saúde:
Agenda de Saúde Sustentável para as Américas
Problema de saúde:
Objetivo 4: Financiamento para a saúde
Base de dados:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Avaliação econômica em saúde
Idioma:
Chinês
Revista:
Chinese Journal of Biochemical Pharmaceutics
Ano de publicação:
2017
Tipo de documento:
Artigo